Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

893 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial.
Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, Larsen ML, Bendiksen FS, Lindahl C, Szarek M, Tsai J; Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group. Pedersen TR, et al. Among authors: kastelein jj. JAMA. 2005 Nov 16;294(19):2437-45. doi: 10.1001/jama.294.19.2437. JAMA. 2005. PMID: 16287954 Clinical Trial.
Raised serum levels of soluble CD40 ligand in patients with familial hypercholesterolemia: downregulatory effect of statin therapy.
Semb AG, van Wissen S, Ueland T, Smilde T, Waehre T, Tripp MD, Frøland SS, Kastelein JJ, Gullestad L, Pedersen TR, Aukrust P, Stalenhoef AF. Semb AG, et al. Among authors: kastelein jj. J Am Coll Cardiol. 2003 Jan 15;41(2):275-9. doi: 10.1016/s0735-1097(02)02718-3. J Am Coll Cardiol. 2003. PMID: 12535822 Free article. Clinical Trial.
Design and baseline characteristics of the Incremental Decrease in End Points through Aggressive Lipid Lowering study.
Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, Larsen ML, Bendiksen FS, Lindahl C, Palmer G; Incremental Decrease in End Points Through Aggressive Lipid Lowering Study Group. Pedersen TR, et al. Among authors: kastelein jj. Am J Cardiol. 2004 Sep 15;94(6):720-4. doi: 10.1016/j.amjcard.2004.06.003. Am J Cardiol. 2004. PMID: 15374773 Clinical Trial.
Atorvastatin.
van Leuven SI, Kastelein JJ. van Leuven SI, et al. Among authors: kastelein jj. Expert Opin Pharmacother. 2005 Jun;6(7):1191-203. doi: 10.1517/14656566.6.7.1191. Expert Opin Pharmacother. 2005. PMID: 15957972 Review.
HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events.
Barter P, Gotto AM, LaRosa JC, Maroni J, Szarek M, Grundy SM, Kastelein JJ, Bittner V, Fruchart JC; Treating to New Targets Investigators. Barter P, et al. Among authors: kastelein jj. N Engl J Med. 2007 Sep 27;357(13):1301-10. doi: 10.1056/NEJMoa064278. N Engl J Med. 2007. PMID: 17898099 Free article. Clinical Trial.
High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies.
van der Steeg WA, Holme I, Boekholdt SM, Larsen ML, Lindahl C, Stroes ES, Tikkanen MJ, Wareham NJ, Faergeman O, Olsson AG, Pedersen TR, Khaw KT, Kastelein JJ. van der Steeg WA, et al. Among authors: kastelein jj. J Am Coll Cardiol. 2008 Feb 12;51(6):634-42. doi: 10.1016/j.jacc.2007.09.060. J Am Coll Cardiol. 2008. PMID: 18261682 Free article. Clinical Trial.
Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment.
Kastelein JJ, van der Steeg WA, Holme I, Gaffney M, Cater NB, Barter P, Deedwania P, Olsson AG, Boekholdt SM, Demicco DA, Szarek M, LaRosa JC, Pedersen TR, Grundy SM; TNT Study Group; IDEAL Study Group. Kastelein JJ, et al. Circulation. 2008 Jun 10;117(23):3002-9. doi: 10.1161/CIRCULATIONAHA.107.713438. Epub 2008 Jun 2. Circulation. 2008. PMID: 18519851
Lipoprotein predictors of cardiovascular events in statin-treated patients with coronary heart disease. Insights from the Incremental Decrease In End-points Through Aggressive Lipid-lowering Trial (IDEAL).
Holme I, Cater NB, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Larsen ML, Lindahl C, Pedersen TR; Incremental Decrease in End-Points Through Aggressive Lipid-Lowering (IDEAL) Study Group. Holme I, et al. Among authors: kastelein jj. Ann Med. 2008;40(6):456-64. doi: 10.1080/07853890801964955. Ann Med. 2008. PMID: 19160529 Clinical Trial.
Comparison of efficacy and safety of atorvastatin (80 mg) to simvastatin (20 to 40 mg) in patients aged <65 versus >or=65 years with coronary heart disease (from the Incremental DEcrease through Aggressive Lipid Lowering [IDEAL] study).
Tikkanen MJ, Holme I, Cater NB, Szarek M, Faergeman O, Kastelein JJ, Olsson AG, Larsen ML, Lindahl C, Pedersen TR; Incremental DEcrease through Aggressive Lipid Lowering Investigators. Tikkanen MJ, et al. Among authors: kastelein jj. Am J Cardiol. 2009 Mar 1;103(5):577-82. doi: 10.1016/j.amjcard.2008.10.029. Epub 2009 Jan 17. Am J Cardiol. 2009. PMID: 19231315 Clinical Trial.
893 results